Sale!

Neulasta

$3,150.00

Generic Name: pegfilgrastim

Brands: Neulasta

Availability: Prescription needed
Pregnancy: Consult a doctor
Alcohol: No known interactions with light drinking
Drug class: Colony-stimulating factor

What is Neulasta?

Neulastas cancer drug has been specifically developed to combat a particular side effect of breast cancer chemotherapy – neutropenia – which is a low count of white blood cells that leaves patients vulnerable to infection. Taken after each cycle of chemo, Neulasta injection works by stimulating bone marrow to produce more white blood cells which help the body restore its ability to fight infection. The cancer drug has proven effective in cutting down the duration of severe neutropenia to 1.7 days instead of 5-7 days. We guide you through the various stages of cancer giving you advice and providing the best medication for your needs.

Treating Breast Cancer
Breast cancer is cancer that forms in the cells of the breasts. In the United States, this cancer is the most common, second only to skin cancer. … Substantial support for breast cancer awareness and research funding has helped create advances in the diagnosis and treatment of breast cancer.

DESCRIPTION

Pegfilgrastim is a covalent conjugate of recombinant methionyl human G-CSF (filgrastim) and monomethoxypolyethylene glycol. Filgrastim is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Filgrastim is obtained from the bacterial fermentation of a strain of E coli transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of filgrastim. The average molecular weight of pegfilgrastim is approximately 39 kD.

Neulasta is provided in two presentations:

  • Neulasta for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).
  • On-body injector (OBI) for Neulasta is supplied with a prefilled syringe containing 0.64 mL of Neulasta in solution that delivers 0.6 mL of Neulasta in solution when used with the OBI for Neulasta. The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.

The delivered 0.6 mL dose from either the prefilled syringe for manual subcutaneous injection or the OBI for Neulasta contains 6 mg pegfilgrastim (based on protein weight) in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), polysorbate 20 (0.02 mg), sodium (0.02 mg), and sorbitol (30 mg) in Water for Injection, USP.

Reviews

There are no reviews yet.

Be the first to review “Neulasta”

Your email address will not be published. Required fields are marked *

Shopping Cart